XML 45 R27.htm IDEA: XBRL DOCUMENT
v3.25.2

Collaborative Arrangements and Licensing Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
AstraZeneca [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Agreement | During the three and six months ended June 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):
| Three Months Ended |  | Six Months Ended
| June 30, |  | June 30,
|  | 2025 |  |  |  | 2024 |  |  |  | 2025 |  |  |  | 2024 |
Revenue from our relationship with AstraZeneca | $ | 54,288 |  |  | $ | 15,960 |  |  | $ | 74,577 |  |  | $ | 27,645 |
Percentage of total revenue |  | 12 | % |  |  | 7 | % |  |  | 13 | % |  |  | 8 | %
Ono [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Agreement | During the three and six months ended June 30, 2025 and 2024, we earned the following revenue from our relationship with Ono (in thousands, except percentage amounts):
|  | Three Months Ended |  |  |  | Six Months Ended |
|  | June 30, 2025 |  |  |  | June 30, 2025 |
Revenue from our relationship with Ono | $ | 280,000 |  |  | $ | 280,000 |
Percentage of total revenue |  | 62 | % |  |  | 48 | %

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |